Raising Awareness on the Therapeutic Role of Cholecalciferol in CKD: a Multidisciplinary-based Opinion

Overview

Journal Endocrine

Specialty Endocrinology

Date 2017 Jul 21

PMID 28726185

Citations 8

Authors

Sandro Giannini

Sandro Mazzaferro

Salvatore Minisola

Luca De Nicola

Maurizio Rossini

Mario Cozzolino

Affiliations

Soon will be listed here.

Abstract

Vitamin D is recognized to play an essential role in health and disease. In kidney disease, vitamin D analogs have gained recognition for their involvement and potential therapeutic importance. Nephrologists are aware of the use of oral native vitamin D supplementation, however, uncertainty still exists with regard to the use of this treatment option in chronic kidney disease as well as clinical settings related to chronic kidney disease, where vitamin D supplementation may be an appropriate therapeutic choice. Two consecutive meetings were held in Florence in July and November 2016 comprising six experts in kidney disease (N = 3) and bone mineral metabolism (N = 3) to discuss a range of unresolved issues related to the use of cholecalciferol in chronic kidney disease. The panel focused on the following six key areas where issues relating to the use of oral vitamin D remain controversial: (1) vitamin D and parathyroid hormone levels in the general population, (2) cholecalciferol in chronic kidney disease, (3) vitamin D in cardiovascular disease, (4) vitamin D and renal bone disease, (5) vitamin D in rheumatological diseases affecting the kidney, (6) vitamin D and kidney transplantation.

Citing Articles

Management of fracture risk in CKD-traditional and novel approaches.

Haarhaus M, Aaltonen L, Cejka D, Cozzolino M, de Jong R, DHaese P Clin Kidney J. 2023; 16(3):456-472.

PMID: 36865010 PMC: 9972845. DOI: 10.1093/ckj/sfac230.

Definition, Assessment, and Management of Vitamin D Inadequacy: Suggestions, Recommendations, and Warnings from the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS).

Bertoldo F, Cianferotti L, DI Monaco M, Falchetti A, Fassio A, Gatti D Nutrients. 2022; 14(19).

PMID: 36235800 PMC: 9573415. DOI: 10.3390/nu14194148.

The role of vitamin D in perinatology. An up-to-date review.

Ciebiera M, Wojtyla C, Lukaszuk K, Zgliczynska M, Zareba K, Rawski W Arch Med Sci. 2021; 17(4):992-1005.

PMID: 34336027 PMC: 8314414. DOI: 10.5114/aoms.2019.81747.

Vitamin D Effects on Bone Homeostasis and Cardiovascular System in Patients with Chronic Kidney Disease and Renal Transplant Recipients.

Cianciolo G, Cappuccilli M, Tondolo F, Gasperoni L, Zappulo F, Barbuto S Nutrients. 2021; 13(5).

PMID: 33922902 PMC: 8145016. DOI: 10.3390/nu13051453.

Osteomalacia and Vitamin D Status: A Clinical Update 2020.

Minisola S, Colangelo L, Pepe J, Diacinti D, Cipriani C, Rao S JBMR Plus. 2021; 5(1):e10447.

PMID: 33553992 PMC: 7839817. DOI: 10.1002/jbm4.10447.

References

Coen G, Taccone Gallucci M, Bonucci E, Ballanti P, Bianchi A, Bianchini G . 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone. Miner Electrolyte Metab. 1983; 9(1):19-27. View

Xiang W, Kong J, Chen S, Cao L, Qiao G, Zheng W . Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2004; 288(1):E125-32. DOI: 10.1152/ajpendo.00224.2004. View

Ewers B, Gasbjerg A, Moelgaard C, Frederiksen A, Marckmann P . Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr. 2008; 87(2):431-7. DOI: 10.1093/ajcn/87.2.431. View

Motiwala S, Wang T . Vitamin D and cardiovascular risk. Curr Hypertens Rep. 2012; 14(3):209-18. DOI: 10.1007/s11906-012-0262-y. View

Cianciolo G, Galassi A, Capelli I, Angelini M, La Manna G, Cozzolino M . Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. Am J Nephrol. 2016; 43(6):397-407. DOI: 10.1159/000446863. View

de Boer I, Ioannou G, Kestenbaum B, Brunzell J, Weiss N . 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007; 50(1):69-77. DOI: 10.1053/j.ajkd.2007.04.015. View

Cipriani C, Romagnoli E, Pepe J, Russo S, Carlucci L, Piemonte S . Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. J Clin Endocrinol Metab. 2013; 98(7):2709-15. DOI: 10.1210/jc.2013-1586. View

Mok C, Birmingham D, Leung H, Hebert L, Song H, Rovin B . Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford). 2011; 51(4):644-52. DOI: 10.1093/rheumatology/ker212. View

Ala-Houhala M, Vahavihu K, Snellman E, Hasan T, Kautiainen H, Karisola P . A narrow-band ultraviolet B course improves vitamin D balance and alters cutaneous CYP27A1 and CYP27B1 mRNA expression levels in haemodialysis patients supplemented with oral vitamin D. Nephron Clin Pract. 2013; 124(1-2):17-22. DOI: 10.1159/000355010. View

10.

Luo X, Yang M, Wu F, Wu L, Chen L, Tang Z . Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus. 2011; 21(1):53-9. DOI: 10.1177/0961203311422709. View

11.

Agarwal R . Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?. Kidney Int. 2010; 77(11):943-5. DOI: 10.1038/ki.2010.77. View

12.

Skaaby T, Nystrup Husemoen L, Thuesen B, Linneberg A . Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease. Endocrine. 2015; 50(1):231-8. DOI: 10.1007/s12020-015-0547-4. View

13.

Schneider L, Dos Santos A, Santos M, Mendonca da Silva Chakr R, Monticielo O . Vitamin D and systemic lupus erythematosus: state of the art. Clin Rheumatol. 2014; 33(8):1033-8. DOI: 10.1007/s10067-014-2530-5. View

14.

Gorini A, Costanzo A, Egan C, di Luzio Paparatti U . Renal status in adult volunteers in central Italy: results from Family Abbott Renal Disease Monitoring Project (FARM) study. J Nephrol. 2011; 25(4):523-32. DOI: 10.5301/jn.5000027. View

15.

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

16.

Souberbielle J, Brazier F, Piketty M, Cormier C, Minisola S, Cavalier E . How the reference values for serum parathyroid hormone concentration are (or should be) established?. J Endocrinol Invest. 2016; 40(3):241-256. DOI: 10.1007/s40618-016-0553-2. View

17.

Douthat W, Chiurchiu C, Massari P . New options for the management of hyperparathyroidism after renal transplantation. World J Transplant. 2013; 2(3):41-5. PMC: 3782233. DOI: 10.5500/wjt.v2.i3.41. View

18.

Pilz S, Iodice S, Zittermann A, Grant W, Gandini S . Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011; 58(3):374-82. DOI: 10.1053/j.ajkd.2011.03.020. View

19.

Xu L, Wan X, Huang Z, Zeng F, Wei G, Fang D . Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials. PLoS One. 2013; 8(4):e61387. PMC: 3634086. DOI: 10.1371/journal.pone.0061387. View

20.

Eastell R, Brandi M, Costa A, DAmour P, Shoback D, Thakker R . Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99(10):3570-9. DOI: 10.1210/jc.2014-1414. View